Target intelligence / Profile preview

JunB proto-oncogene, AP-1 transcription factor subunit (JUNB)

Target
JUNB
Molecular classification
Transcription factor, AP-1 complex component, Basic leucine zipper (bZIP) protein
01

Overview

JunB proto-oncogene, AP-1 transcription factor subunit (JUNB), is a DNA-binding transcription factor belonging to the activator protein 1 (AP-1) complex, characterized by a basic leucine zipper (bZIP) domain for dimerization and DNA binding. It is encoded on chromosome 19p13 and regulates diverse physiological processes including placental and cardiovascular development, bone formation, epidermal homeostasis, as well as the differentiation and function of immune cells such as T cells, macrophages, dendritic cells, and neutrophils. JunB acts via the AP-1 complex, forming homodimers or heterodimers (frequently with Fos or BATF proteins) to regulate gene expression in response to external stimuli such as cytokines, stress, and growth factors. Dysregulation of JunB is implicated in several cancers, particularly myeloid leukemias where its loss is linked to enhanced proliferation and reduced differentiation of hematopoietic stem cells. JunB is also involved in the regulation of inflammatory responses and the tumor microenvironment. Restoration of JunB expression via epigenetic drugs has been investigated as a therapeutic strategy in certain leukemias[1][2].

Other names
JunBTranscription factor JunBAP-1 transcription factor subunit JunBAP-1, activator protein 1jun B proto-oncogenetranscription factor AP-1 subunit JunBtranscription factor jun-B
02

Mechanism of action

Epigenetic modulation to restore JunB expression (histone deacetylase inhibition, DNA demethylation); Indirect restoration of differentiation and inhibition of proliferation (via AP-1 pathway modulation)

03

Biological functions

Gene expression regulationCell differentiationCell proliferationImmune response modulationTissue homeostasisAngiogenesisSenescenceMyelopoiesisApoptosis
04

Disease associations

CancerLeukemia (acute myeloid leukemia, acute promyelocytic leukemia, T-cell acute lymphoblastic leukemia)InflammationCardiovascular diseaseOther conditions linked to immune and tissue dysfunction
05

Safety considerations

Potential for off-target effects due to AP-1 complex’s broad role in cell proliferation and immune responsePossible impact on normal hematopoiesis and immune function when modulating JunB activity
06

Interacting drugs

Panobinostat

3 more in the full profile.

07

Biomarkers

JunB expression level in hematopoietic cells (as a marker for leukemia progression or differentiation)Down-regulation in acute myeloid leukemia (AML)

Beyond the preview

Go deeper on JunB proto-oncogene, AP-1 transcription factor subunit (JUNB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on JunB proto-oncogene, AP-1 transcription factor subunit (JUNB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call